newsfilter
← Latest News
GlobeNewswire·

PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES

PETV
  • PetVivo Holdings, Inc. released two research abstracts evaluating the intra-articular administration of its Spryng® with OsteoCushion® collagen-elastin hydrogel in rhesus macaques with naturally occurring osteoarthritis.
  • The research was conducted in conjunction with the Wisconsin National Primate Research Center at the University of Wisconsin–Madison.
  • Preliminary findings indicate statistically significant increases in walking speed at weeks one, two, & three post-treatment, with a mean improvement of 0.22 ± 0.11 meters per second.
  • Histopathologic evaluation confirmed hydrogel incorporation into the synovial membrane by day 11, with material remaining identifiable through day 28 & showing minimal local inflammatory response.
  • Additional analyses regarding activity monitoring, goniometry, & histochemical characterization are currently ongoing.
  • The abstracts will be presented at the 2026 Association of Primate Veterinarians Workshop (Oct 23), the 2026 AALAS National Meeting (Oct 28), & the 2026 ACVP Annual Meeting (Nov 14–17).
  • Julie Majka, DVM, MS, is the first author of both abstracts, with a broader team including Jennifer Coonen, Nicholas Keuler, Kirsty Husby, Heather Simmons, Puja Basu, Jennifer Hayes, Ricki Colman, & Saverio Capuano III.
  • Spryng® is a commercially available, veterinarian-administered medical device composed of extracellular matrix microparticles used to manage lameness & joint-related afflictions in companion animals & horses.
  • PetVivo Holdings, Inc. holds a portfolio of twelve issued & pending patents & six trade secrets protecting its biomaterials & production methods.
  • The company maintains that longer-term outcomes & applicability to other species remain subjects for future research.